Role of Imunomet in upper respiratory tract disorders: A randomized double blind placebo controlled clinical trial

Upper respiratory tract disorders comprise 87.5% of total acute respiratory morbidity in children in India. This has become a major community health problem. The symptoms are often self limiting and many a time caused by viruses, however, recurrent attacks may lead to distinct morbidity. This study was conducted in hospital outpatient department on children who have been attending at frequent interval with complaints of sore throat, pharyngitis, tonsillitis. They were administered Imunomet syrup or tablet for a period of 8 weeks. At the end of the treatment, about 84% patients responded well to treatment and 16% patients had fair response to treatment. None of the patients showed any adverse reaction to treatment. The syrup was found to be palatable.